Ocugen (OCGN) Q2 FY26 earnings call

Ocugen advanced its gene therapy platform with significant regulatory and clinical milestones in Q2 FY26, including FDA clearance for OCU410's Phase 3 trial and RMAP designation, and completing enrollment for OCU400 and OCU410ST. The company also secured $130 million in financing, extending its cash runway into 2028, positioning it for multiple BLA submissions by 2028. Management outlined a strategy for global commercialization and capital allocation.